Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Timothy_C._Crew
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:filed_for_Chapter_11_bankruptcy |
2023
|
| gptkbp:formerly_listed_on |
gptkb:NYSE
|
| gptkbp:founded |
1942
|
| gptkbp:founder |
gptkb:William_S._Lannett
|
| gptkbp:headquarters_location |
gptkb:Trevose,_Pennsylvania,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lannett Company, Inc.
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:numberOfEmployees |
approximately 700
|
| gptkbp:products |
generic pharmaceuticals
|
| gptkbp:specializesIn |
injectable pharmaceuticals
liquid pharmaceuticals oral solid dosage forms |
| gptkbp:stockSymbol |
gptkb:LCINQ
|
| gptkbp:tradedOn |
gptkb:OTC:_LCINQ
|
| gptkbp:website |
https://www.lannett.com/
|
| gptkbp:bfsParent |
gptkb:LGRX
|
| gptkbp:bfsLayer |
7
|